• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5107272)   Today's Articles (2810)
For: Qin Y, Jiang B, Jiang Q, Jiang H, Li J, Zhang Y, Zhu H, Li L, Chen S, Liu Y, Huang X. Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-up. Ann Hematol 2008;88:37-41. [DOI: 10.1007/s00277-008-0548-y] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2008] [Accepted: 06/23/2008] [Indexed: 11/30/2022]
Number Cited by Other Article(s)
1
Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China. Clin Drug Investig 2017;38:79-86. [DOI: 10.1007/s40261-017-0587-z] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
2
Second-generation tyrosine kinase inhibitors combined with stem cell transplantation in patients with imatinib-refractory chronic myeloid leukemia. Am J Med Sci 2014;347:439-45. [PMID: 24553398 DOI: 10.1097/maj.0000000000000186] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
3
Zhu Y, Qian SX. Clinical efficacy and safety of imatinib in the management of Ph(+) chronic myeloid or acute lymphoblastic leukemia in Chinese patients. Onco Targets Ther 2014;7:395-404. [PMID: 24623982 PMCID: PMC3949731 DOI: 10.2147/ott.s38846] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]  Open
4
Qin YZ, Jiang Q, Jiang H, Li JL, Li LD, Zhu HH, Lai YY, Lu XJ, Liu YR, Jiang B, Huang XJ. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABLIS or log reduction from the baseline level? Leuk Res 2013;37:1035-40. [DOI: 10.1016/j.leukres.2013.06.003] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2013] [Revised: 05/30/2013] [Accepted: 06/01/2013] [Indexed: 11/15/2022]
5
Bendit I, Sanabani SS, Conchon M, Serpa M, Novaes MMY, Nardinelli L, Pereira TDM, Tucunduva L, Ferreira PDB, Dorlhiac-Llacer PE, Fischer Chamone DDA. Evaluation of long-term outcomes, cytogenetic and molecular responses with imatinib mesylate in early and late chronic-phase chronic myeloid leukemia: a report from a single institute. Acta Haematol 2012;128:223-32. [PMID: 22922489 DOI: 10.1159/000339696] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2012] [Accepted: 05/23/2012] [Indexed: 01/04/2023]
6
Fava C, Kantarjian H, Cortes J. Molecular resistance: an early indicator for treatment change? CLINICAL LYMPHOMA, MYELOMA & LEUKEMIA 2012;12:79-87. [PMID: 22285607 PMCID: PMC5539978 DOI: 10.1016/j.clml.2011.12.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/17/2011] [Revised: 12/01/2011] [Accepted: 12/01/2011] [Indexed: 11/27/2022]
7
Radich JP. Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia. Cancer 2011;118:300-11. [PMID: 21717440 DOI: 10.1002/cncr.26280] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2010] [Revised: 04/14/2011] [Accepted: 04/21/2011] [Indexed: 12/26/2022]
8
Huang XJ, Xu LP, Liu KY, Liu DH, Chen H, Liu YR, Chen YH, Han W, Wang Y. Individualized Intervention Guided by BCR-ABL Transcript Levels after HLA-Identical Sibling Donor Transplantation Improves HSCT Outcomes for Patients with Chronic Myeloid Leukemia. Biol Blood Marrow Transplant 2011;17:649-56. [DOI: 10.1016/j.bbmt.2010.07.023] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2010] [Accepted: 07/27/2010] [Indexed: 10/19/2022]
9
Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients. Ann Hematol 2010;90:47-52. [PMID: 20697894 DOI: 10.1007/s00277-010-1039-5] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2010] [Accepted: 07/27/2010] [Indexed: 10/19/2022]
10
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia 2009;23:1628-33. [PMID: 19641527 DOI: 10.1038/leu.2009.156] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
11
Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population. Int J Hematol 2009;89:445-451. [DOI: 10.1007/s12185-009-0292-7] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2008] [Revised: 01/18/2009] [Accepted: 03/03/2009] [Indexed: 12/17/2022]
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA